Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ: OMER )

8.900 +0.150 (+1.71%)
Streaming Delayed Price Updated: 10:12 AM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,632
Open 8.750
Bid (Size) 8.880 (1)
Ask (Size) 8.930 (10)
Prev. Close 8.750
Today's Range 8.740 - 8.990
52wk Range 2.612 - 13.60
Shares Outstanding 62,855,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
From Omeros Corporation
Via Business Wire
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
From Omeros Corporation
Via Business Wire

Performance

YTD
-9.55%
-9.55%
1 Month
-1.06%
-1.06%
3 Month
-25.27%
-25.27%
6 Month
+120.30%
+120.30%
1 Year
+97.78%
+97.78%

More News

Read More
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
From Omeros Corporation
Via Business Wire
Earnings Scheduled For November 13, 2024
Via Benzinga
Earnings Outlook For Omeros
Via Benzinga
OMER Stock Earnings: Omeros Misses EPS for Q2 2024
Via InvestorPlace
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
From Omeros Corporation
Via Business Wire
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline
Via Benzinga
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges
Via Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge
Via Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
From Omeros Corporation
Via Business Wire
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
From Omeros Corporation
Via Business Wire
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
Via Benzinga
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
From Omeros Corporation
Via Business Wire
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
Via Benzinga
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
From Omeros Corporation
Via Business Wire
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Omeros Corporation Reports Third Quarter 2024 Financial Results
From Omeros Corporation
Via Business Wire
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
From Omeros Corporation
Via Business Wire
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
From Omeros Corporation
Via Business Wire
Omeros Corporation Reports Second Quarter 2024 Financial Results
From Omeros Corporation
Via Business Wire
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
From Omeros Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.